No Interaction Expected
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence:
The pharmacokinetics of testosterone administered either intramuscularly or subcutaneously were evaluated in adolescent transgender men (n=24, age 17-24 years) receiving oral PrEP with emtricitabine/tenofovir-DF. PrEP did not significantly alter testosterone total and free concentrations. AUC and Cmax of total testosterone both decreased by 9% with PrEP; AUC and Cmax of free testosterone decreased by 12% and 11% with PrEP.
The pharmacokinetics of testosterone administered either intramuscularly or subcutaneously was evaluated in adolescent transgender men (n=24, median [IQR] age: 21 [17-24]) receiving oral PrEP with emtricitabine/tenofovir-DF. Hormone concentrations were measured at baseline and after 2-3 weeks of daily PrEP dosing. The geometric mean AUC and Cmax for testosterone at baseline and on PrEP were 0.91 and 0.91 for total concentrations, and 0.88 and 0.89 for free concentrations. PrEP did not significantly alter serum estradiol pharmacokinetics in transgender women or free and total testosterone pharmacokinetics in transgender men.
Exogenous hormone pharmacokinetics in transgender adolescents receiving oral TDF/FTC. Yager JL, Brooks K, Brothers J, et al. Virtual Conference on Retroviruses and Opportunistic Infections, March 2021, Abstract 366.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking